Sanofi (SNYNF) Convertible Debt (2020 - 2021)
Sanofi's (SNYNF) quarterly Convertible Debt came in at $24.4 billion in Q2 2021, down 9.71% quarter-over-quarter from $27.0 billion in Q4 2020.
Sanofi (SNYNF) Convertible Debt (2020 - 2021) Analysis & Trends
Sanofi has disclosed Convertible Debt across 2 years of filings, most recently posting $24.4 billion for Q2 2021.
- Convertible Debt for Q2 2021 came in at $24.4 billion, changed N/A year-over-year; the trailing twelve-month figure through Jun 2021 was $24.4 billion (changed N/A YoY), and the FY2020 annual result was $25.8 billion, changed N/A from the prior year.
- Convertible Debt came in at $24.4 billion for Q2 2021 at Sanofi, down from $27.0 billion in the prior quarter.
- In the past five years, Convertible Debt ranged from a high of $27.0 billion in Q4 2020 to a low of $24.4 billion in Q2 2021.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Gsk | 96,436,181.12 Bn | 96,436,176.16 Bn | 7.76 Bn |
| 2 | Eli Lilly | 1,017.30 Bn | 1,012.01 Bn | 16.22 Bn |
| 3 | Johnson & Johnson | 579.61 Bn | 557.55 Bn | 15.96 Bn |
| 4 | AbbVie | 402.30 Bn | 392.96 Bn | 10.78 Bn |
| 5 | Merck | 294.24 Bn | 288.59 Bn | 12.09 Bn |
| 6 | Amgen | 191.82 Bn | 179.78 Bn | 5.87 Bn |
| 7 | Gilead Sciences | 155.93 Bn | 148.21 Bn | 5.52 Bn |
| 8 | Pfizer | 149.05 Bn | 136.28 Bn | -1.21 Bn |
| 9 | Bristol Myers Squibb | 116.33 Bn | 105.88 Bn | 8.07 Bn |
| 10 | Sanofi | - | - | 9.49 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2021 | 24.36 Bn |
| Dec 31, 2020 | 26.98 Bn |